NCT02603822View on ClinicalTrials.gov

Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 17, 2018

Study Completion Date

July 17, 2018

Conditions
Impaired Small Intestinal Permeability
Interventions
DIETARY_SUPPLEMENT

12C mannitol

12C mannitol 100 mg

DRUG

Indomethacin

Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.

DIETARY_SUPPLEMENT

13C mannitol

13C mannitol 100 mg

DIETARY_SUPPLEMENT

Lactulose

lactulose 1 g

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT02603822 - Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability | Biotech Hunter | Biotech Hunter